YOLFTbeta
30

Suzhou Highfine Biotech Co., Ltd.

301393 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

53.59CNY-1.51 (-2.74%)

Price History

Full chart

Market Stats

Previous Close55.10
Open54.60
Day Range53.05 – 55.30
52-Week Range46.49 – 74.68
Volume1.76M
Market Cap5.83B
P/E (TTM)46.90
Forward P/E0.00
EPS1.15
Dividend Yield0.75%
Beta0.72
50-Day Avg59.72
200-Day Avg57.56

About

Suzhou Highfine Biotech Co., Ltd. manufactures and sells chemicals for pharmaceutical research and development, and API production companies in China. The company's products include building blocks, protein reagents, protein crosslinkers, liposomes, ionic liquids, protective amino acids, unnatural amino acids, nucleotide reagents, etc. Its products are used in fields of peptide, nucleotide, and pharmaceutical synthesis. Suzhou Highfine Biotech Co., Ltd. was founded in 2003 and is based in Suzhou, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Yong Zhu
  • Employees678
  • HeadquartersNo.1, Changting Road, Suzhou, China, 215151, China
  • Websitehttps://www.highfine.com

Leadership

  • Mr. Yong ZhuChairman & GM · b. 1971
  • Ms. Xiaoyan WangFinance Manager, Accounting Supervisor & Head of the Accounting Agency · b. 1980
  • Mr. Xu JieDirector & Deputy GM · b. 1979
  • Mr. Minjie LvDirector & Deputy GM · b. 1983
  • Mr. Xuegen LuDirector & Deputy GM · b. 1982
  • Mr. Yu LuoR&D Director and Director · b. 1978
  • Mr. Shengjun DongDeputy GM & Secretary of the Board · b. 1978
  • Ms. Jinfeng LiHead of the Sales Department · b. 1987

Financials

Income Statement

Currency: CNY2022-12-312023-12-312024-12-312025-12-31
Total Revenue447.46M388.79M451.87M602.26M
Growth (%)--13.11%+16.22%+33.28%
Cost of Revenue253.89M238.90M269.85M392.51M
Gross Profit193.56M149.89M182.02M209.75M
Gross Margin43.26%38.55%40.28%34.83%
Operating Expense48.56M61.28M70.33M93.11M
Operating Income145.01M88.61M111.70M116.64M
Operating Margin32.41%22.79%24.72%19.37%
EBITDA161.09M126.72M174.72M167.86M
EBITDA Margin36.00%32.59%38.67%27.87%
Net Income129.37M98.97M134.05M114.65M
Net Income Margin28.91%25.46%29.67%19.04%
R&D22.26M28.47M35.99M40.93M
R&D as % of Total Revenue4.97%7.32%7.97%6.80%
Interest Expense482.38K45.27K91.29K698.04K
Interest Expense % of Total Revenue0.11%0.01%0.02%0.12%

Balance Sheet

Currency: CNY2022-12-312023-12-312024-12-312025-12-31
Total Assets600.05M2.29B2.35B2.65B
Total Liabilities117.77M75.08M81.35M295.24M
Total Equity482.28M2.21B2.27B2.35B
Cash99.32M1.74B361.08M408.66M

Cash Flow

Currency: CNY2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow138.67M87.83M126.37M77.67M
Capital Expenditure81.40M120.47M107.75M210.63M
Free Cash Flow57.27M-32.64M18.62M-132.96M
Dividends Paid20.25M27.00M40.19M43.44M
FCF to OCF41.30%-37.17%14.73%-171.18%
Dividend Paid to FCF35.36%-82.71%215.87%-32.67%

Earnings

Report DateSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
EPS Estimate-------------
EPS Actual0.190.190.280.340.290.350.320.380.220.140.310.350.34
Surprise-------------
Timing-------------

Key Statistics & Ratios

Market Cap5.83B
Enterprise Value4.91B
Trailing P/E46.90
Forward P/E0.00
Price / Sales7.69
Price / Book2.39
EPS1.15
Book Value22.78
Revenue (TTM)757.31M
Gross Profit (TTM)239.80M
EBITDA163.19M
Profit Margin16.29%
Operating Margin18.35%
Return on Equity4.93%
Return on Assets2.66%
Shares Outstanding108.00M
Shares Float39.97M
Beta0.72
Dividend Yield0.75%
Dividend Rate0.41
Payout Ratio35.38%

Dividends

20261×
0.15Nov 10, 2026